Subscribe to our Newsletters !!
On September 16, 2024, HiMedia Laboratories proudl
Particles in suspensions are abundant in biologica
Dräger India is proud to announce the launch of t
Husky Technologies™ is excited to announce a maj
Alembic Pharmaceuticals Limited (Alembic) today an
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Micr
Zydus Cadila has gotten last endorsement from the USFDA to showcase Meclizine Hydrochloride Tablets (US RLD: Antivert Tablets) in the qualities of 12.5 mg and 25 mg.
The medication will be produced at the gathering’s assembling office at SEZ, Ahmedabad, Cadila said in the recording.
Meclizine is an antihistamine that is utilized to forestall and treat queasiness, spewing, and discombobulation brought about by movement ailment. It might likewise be utilized to decrease discombobulation and loss of parity (vertigo) brought about by inward ear issues.
The gathering presently has 292 endorsements and has so far documented more than 390 ANDAs since the beginning of the recording procedure in FY2003-04.
Cadila Healthcare Ltd is as of now exchanging at Rs367.35, up by Rs0.4 or 0.11% from its past shutting of Rs366.95 on the BSE.
The scrip opened at Rs370 and has contacted a high and low of Rs373.35 and Rs363.15 separately.
